Nektar Therapeutics (NKTR) CEO Howard W. Robin Sells 93,458 Shares of Stock
Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 93,458 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, November 17th. The stock was sold at an average price of $13.88, for a total value of $1,297,197.04. Following the completion of the transaction, the chief executive officer now directly owns 122,908 shares in the company, valued at $1,705,963.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Howard W. Robin also recently made the following trade(s):
- On Tuesday, October 4th, Howard W. Robin sold 87,500 shares of Nektar Therapeutics stock. The stock was sold at an average price of $17.06, for a total value of $1,492,750.00.
- On Thursday, September 1st, Howard W. Robin sold 87,500 shares of Nektar Therapeutics stock. The stock was sold at an average price of $17.83, for a total value of $1,560,125.00.
Shares of Nektar Therapeutics (NASDAQ:NKTR) traded down 3.95% during mid-day trading on Monday, reaching $13.39. The company had a trading volume of 294,074 shares. Nektar Therapeutics has a 12-month low of $10.52 and a 12-month high of $19.98. The firm’s 50 day moving average is $14.36 and its 200-day moving average is $15.70. The stock’s market capitalization is $2.05 billion.
Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.04. The firm had revenue of $36.30 million for the quarter, compared to analyst estimates of $32.42 million. Nektar Therapeutics had a negative return on equity of 8,769.15% and a negative net margin of 98.87%. The business’s revenue for the quarter was down 39.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.06) earnings per share. On average, analysts expect that Nektar Therapeutics will post ($1.07) earnings per share for the current fiscal year.
Several brokerages have recently weighed in on NKTR. Jefferies Group reissued a “buy” rating on shares of Nektar Therapeutics in a report on Thursday, September 8th. Zacks Investment Research raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, September 21st. Piper Jaffray Cos. reissued an “overweight” rating and set a $21.00 price objective (up previously from $17.00) on shares of Nektar Therapeutics in a report on Friday, August 5th. Brean Capital reissued a “buy” rating and set a $18.00 price objective on shares of Nektar Therapeutics in a report on Friday, August 5th. Finally, Aegis began coverage on Nektar Therapeutics in a report on Tuesday, November 8th. They set a “buy” rating and a $21.00 price objective on the stock. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $20.50.
Hedge funds have recently added to or reduced their stakes in the stock. Bridger Management LLC acquired a new stake in Nektar Therapeutics during the first quarter valued at about $48,359,000. Cormorant Asset Management LLC raised its position in shares of Nektar Therapeutics by 161.4% in the first quarter. Cormorant Asset Management LLC now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $27,500,000 after buying an additional 1,234,844 shares during the period. Westfield Capital Management Co. LP purchased a new position in shares of Nektar Therapeutics during the second quarter worth $17,247,000. BlackRock Fund Advisors raised its position in shares of Nektar Therapeutics by 7.3% in the third quarter. BlackRock Fund Advisors now owns 10,970,974 shares of the biopharmaceutical company’s stock worth $188,481,000 after buying an additional 749,496 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Nektar Therapeutics by 97.8% in the third quarter. Price T Rowe Associates Inc. MD now owns 1,156,400 shares of the biopharmaceutical company’s stock worth $19,867,000 after buying an additional 571,900 shares during the period. Hedge funds and other institutional investors own 86.69% of the company’s stock.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.
Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.